DIACEUTICS PLC

Remuneration Information • Jun 7, 2021

National Storage Mechanism | Additional information

RNS Number : 0886B

Diaceutics PLC

07 June 2021

7 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified on 4 June 2021 that Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have purchased ordinary shares ("Shares") on behalf of Susanne Munksted (PDMR), in respect of her initial purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

As announced on 30 April 2021, under the SIP Scheme, the Company will match this purchase with a matched share award being the grant of a single one-off option over an equivalent number of Shares purchased by the employee, over the forthcoming period to July 2022 and subsequent 12 month periods thereafter, in the proportion of 2:1 for all purchases up to and including April 2022 and 1:1 for all purchases thereafter. The options will be formally granted in the future, expected to be within July, at an exercise price of nil.

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Susanne Munksted
2	Reason for notification
a.	Position/Status	Managing Director and PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares to be matched by the future grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")
c.	Price(s) and volume(s)		Share purchase:
	Price(s)	Volume(s)
129.00 p	111
Matching option award: Option over 222 Shares (exercise price: nil) to be awarded in July 2021
d.	Date of the transaction	Share purchase: 28 May 2021 (Company informed  4 June 2021) Option award: To be formally entered into in July 2021
e.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Future option award: Off-Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKOBBOBKDKAK